ValGenesis Inc.

ValGenesis Inc. is a privately held company headquartered in Santa Clara, California, specializing in digital validation lifecycle management solutions for the life sciences industry. The company's core mission is to bring digital order to validation in life sciences, aiming to accelerate the delivery of consistent, safe products by transforming quality and compliance through efficiency, accuracy, and confidence.

ValGenesis offers integrated and smart solutions that support the digital transformation of the life sciences industry, including pharmaceutical, biotech, and medical device sectors. Its flagship offering is the AI-powered ValGenesis Smart GxP™ Platform, which unifies validation, quality, and manufacturing processes. This platform includes key applications such as ValGenesis iVal™, iClean™, iOps™, iCMC™, and iCPV™, designed to streamline various aspects of the validation lifecycle, computer software assurance (CSA), computer system validation (CSV), and risk management.

As a market leader in enterprise validation lifecycle management systems, ValGenesis has recently focused on AI-driven innovation. In June 2025, the company launched ValGenesis Smart GxP™, the first AI-enabled platform to unify validation and process development, followed by the introduction of the next generation of VAL™ (ValGenesis AI) in April 2026. ValGenesis secured $16 million in strategic financing in July 2025 from Bridge Bank and Morgan Stanley Expansion Capital to support its global expansion and accelerate product innovation in AI-assisted validation. Dr. Siva Samy serves as the CEO and Chief Product Strategist, leading the company's strategic direction.